Should anti-EGFR mAbs be discontinued for conversion surgery in untreated right-sided metastatic colorectal cancer? A systematic review and meta-analysis

BACKGROUND: Previous studies have demonstrated that left-sided tumors have better prognoses than right-sided tumors in RAS wild-type mCRC (metastatic colorectal cancer) patients, while anti-EGFR mAbs appear to have no advantage compared with bevacizumab for right-sided tumors in these patients. Neve...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Datian, Zhang, Xiang, Gao, Guangyi, Shen, Lili, Xie, Jiaqi, Qian, Xiaoping, Wang, Huiyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176519/
https://www.ncbi.nlm.nih.gov/pubmed/30296945
http://dx.doi.org/10.1186/s12957-018-1502-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176519/
https://www.ncbi.nlm.nih.gov/pubmed/30296945
http://dx.doi.org/10.1186/s12957-018-1502-7

Ejemplares similares